Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
The product will be manufactured at Lupin’s Nagpur facility in India
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Phase 3 data expected in the second half of 2024
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
Subscribe To Our Newsletter & Stay Updated
